Pure Global

Peripheral blood vessel hypoxic shadow covered with paclitaxel - Vietnam Registration 2400478ĐKLH/BYT-HTTB

Access comprehensive regulatory information for Peripheral blood vessel hypoxic shadow covered with paclitaxel in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại D medical device is registered under number 2400478ĐKLH/BYT-HTTB and manufactured by Lutonix, Inc.. The authorized representative in Vietnam is CÔNG TY TNHH DƯỢC PHẨM VÀ THIẾT BỊ Y TẾ LONG BÌNH.

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
300,000+ Devices
2400478ĐKLH/BYT-HTTB
Registration Details
Vietnam MOH Registration: 2400478ĐKLH/BYT-HTTB
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

Peripheral blood vessel hypoxic shadow covered with paclitaxel
VN: Bóng nong mạch máu ngoại vi phủ thuốc paclitaxel
Risk Class TTBYT Loại D

Registration Details

2400478ĐKLH/BYT-HTTB

17003044/ĐKLH-BYT-TB-CT

Theo theo phụ lục

Theo phụ lục

Company Information

Theo theo phụ lục

Lutonix, Inc.

Technical Details

LUTONIX 018 Drug Coated Balloon Catheter is indicated for percutaneous transluminal angioplasty (PTA) of the popliteal artery and for the treatment of chronic total occlusions and to reduce the rate of restenosis. Additionally, the LUTONIX 018 Drug Coated Balloon Catheter is indicated for percutaneous transluminal angioplasty (PTA) of the native arteriovenous fistula or arteriovenous graft in hemodialysis patients or for native vessels in patients with arteriovenous grafts to improve outflow and reduce the rate of restenosis. LUTONIX 018 Drug Coated Balloon Catheter is indicated for the treatment of lesions up to 290mm in length or up to approximately 7.6mg of paclitaxel per patient

Dates and Status

Apr 10, 2024